Rheumatoid arthritis and cardiovascular disease;Artrite reumatóide e doenças cardiovasculares

Revista Brasileira de Reumatologia

Volumn 46, Issue SUPPL. 1, 2006, Pages 60-65

  Torigoe, Dawton Yukito ^a,b   Laurindo, Iêda Maria Magalhães ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Cardiovascular disease; Coronary disease; Rheumatoid arthritis

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY RISK; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MORTALITY; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 51549118478     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0482-50042006000700010     Document Type: Review

References (109)

1. Mikkelsen WM, Dodge HJ, Duff IF, Kato H. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh. Michigan, 1959-60. J Chronic Dis 20: 351-359, 1967.
2. Lawrence JS, Bremner JM, Ball J, Burch TA. Rheumatoid arthritis in a subtropical population. Ann. Rheum Dis 25: 59-66, 1966.
3. Marques Neto JF, Gonçalves HT, Langen LFOB et al. Estudo multicêntrico da prevalência da artrite reumatóide do adulto em amostras da população brasileira. Rev Bras Reumatol 33: 169-173, 1993.
4. Senna ER, De Barros AL, Silva EO et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 31: 594-597, 2004.
5. Pasceri V, Yeh ETH. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100: 2124-2126, 1999.
6. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30: 36-40, 2003.
7. Snow MH, Mikuls TR, Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17: 234-41, 2005.
8. Sattar N, McInnes IB. Vascular comorbity in rheumatoid arthrtis: potential mechanisms and solutions. Curr Opin Rheumatol 17: 286-292, 2005.
9. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 249: 553-556, 1953.
10. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 23: 92-99, 1984.
11. Symmons DP, Jones MA, Scott DA, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25: 1072-1077, 1998.
12. Krause D, Schleusser B, Herborn G, Rau R, Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43: 14-21, 2000.
13. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 11: 81-86, 1982.
14. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 37: 481-494, 1994.
15. Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis 29: 459-467, 1976.
16. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 290: 1797-1799, 1985.
17. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24: 445-551, 1997.
18. Mitchell DM, Spitz PW, Young DY, Bloch DA, Mcshane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 29: 706-14, 1986.
19. Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 29: 29-37, 2000.
20. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 49: 363-369, 1990.
21. Myllykangas-Luosujarvi PA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum 25: 193-202, 1995.
22. Allebeck P, Ahlbonm A, Allender E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: eleven-year follow-up of an epidemiological study. Scand J Rheumatol 10: 301-306, 1981.
23. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughan WK. Severe functional declines, work, disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27: 864-872, 1984.
24. Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum 13: 125-130, 1970.
25. Sokka T, Mottonen T, Hannonen P. Mortality In Early "Saw-tooth" treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 28: 282-287, 1999.
26. Jacobsson LTH, Knowler WC, Pillemer S, Pettitt DJ, Nelson R G et al. Rheumatoid arthritis and mortality: a longitudinal study in Pima Indians. Arthritis Rheum 36: 1045-53, 1993.
27. Lewis P, Hazleman BL, Hanka L, Roberts S. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 39: 457-461, 1980.
28. Linos A, Worthington JW, o'fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 111: 87-98, 1980.
29. Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 44: 1467-1469, 2001.
30. Myllykangas-Luosujarvi PA, Aho K, Kautiannen H, Isomaki HA. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 22: 1065-1067, 1995.
31. Mutru O, Koota K, Isomaki H. Causes of death in autopsied RA patients. Scand J Rheumatol 5: 239-40, 1976.
32. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 58: 11-14, 1999.
33. Kroot E.J, Van Leeuwen MA, Van Rijswiik MH et al. No increase mortality in patients with rheumatoid arthritis: up to 10 years of follow-up from disease onset. Ann Rheum Dis 59: 954-958, 2000.
34. Riise T, Jacobsen BK, Gran JT et al. Total mortality is increased in rheumatoid arthritis: a 17 year prospective study. Clin Rheumatol 20: 123-127, 2001.
35. Mutru O, Laakso M, Isomaki H, Koota K.Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 76: 71-77, 1989.
36. Watson DJ, Rhodes T, Guess HA, All cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK general practice research database. J Rheumatol 30: 1196-202, 2003.
37. Gabriel SE, Crowson CS, O'Fallon WM. Comorbity in arthritis. J Rheumatol 26: 2475-2479, 1999.
38. Nicola PJ, Maradit-Kremers H, Roger VL et al. The risk of congrstive heart failure in the rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52: 412-420, 2005.
39. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107: 1297-1301, 2003.
40. Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study Arthritis Rheum 50: 3729-373, 2004.
41. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-Mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134: 250-256, 1991.
42. Bots ML, Hoffman A, De Jong PT, Grobee DE. Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam study. Ann Epidemiol 6: 147-53, 1996.
43. Kumeda Y, Inaba M, Goto H et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46: 1489-1497, 2002.
44. Park YB, Ahn CW, Choi HK et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46: 1714-1719, 2002.
45. Alkaabi JY, Levison R, Pullar T, Belch JJF. Rheumatoid arthritis and macrovascular disease. Rheumatology 42; 292-297, 2003.
46. Gonzalez-Juataney C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 82: 407-413, 2003.
47. Wilson PW, D'agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847, 1998.
48. Tuomi T, Heliovaara M, Palosuo T, Aho K. Smoking, lung function, and rheumatoid factors. Ann Rheum Dis 49: 753-756, 1990.
49. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarrete smoking and rheumatoid arthritis severity. Ann Rheum Dis 56: 463-469, 1997.
50. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. Rheumatol 27: 630-637, 2000.
51. Wolfe F, Michaud Y, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 48: 1530-1542, 2003.
52. Cisternas M, Gutierrez MA, Klaassen J, Acosta AM, Jacobelli S. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 29: 1619-1622, 2002.
53. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology 42: 607-613, 2003.
54. Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis. Targeting cardiovascular comorbidity. Arthritis Rheum 50: 1734-1739, 2004.
55. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153: 477-484, 1993.
56. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflamatory drugs affect blood pressure? A meta-analysis. Ann. Intern. Med 121: 289-300, 1994.
57. Collins R, Peto R, Macmahon S et al. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335: 827-838, 1990.
58. Svenson KL, Lithell H, Halgreen R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 147: 1912-1916, 1987.
59. Lakatos I, Harsagyi A. Serum total HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 21: 93-6, 1988.
60. Lazarevic MB, Vitic I, Mladenovic V, Myones BL, Skosey J.L, Swedler WI. Dyshpoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 22: 172-178, 1992.
61. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids and lipoproteins in patients with rheumatoid arthritis. Arm Rheum Dis 50: 366-8, 1991.
62. Lorber M, Aviram M, Lina S, Scharf Y, Brook JG. Hypocholesterolemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheum 24: 250-255, 1985.
63. Park YB, Lee SK, Lee WK et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26: 1701-1704, 1999.
64. Lee YH, Choi SI, Ji ID, Seo HS, Song GG. Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19: 324-325, 2000.
65. Boers M, Nurmohamed MT, Doelman CJ et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62: 842-845, 2003.
66. Wallace D.J, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydrixychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89: 322-326, 1990.
67. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96: 254-259, 1994.
68. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28: 780-785, 2001.
69. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Yidney Dis 18: 353-358, 1991.
70. Prokopowitsch AS, Diógenes AHM, Borges CT, Torigoe DY, Kochen J, Laurindo IMM. Leflunomide induces progressive increase in rheumatoid arthritis hpid profile. Arthritis Rheum 46:S164, 2002.
71. Ettinger WH, Goldberg AP, Applebaun-Bowden D, Hazzard WR. Dyshpoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83: 503-508, 1987.
72. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21: 1264-1267, 1994.
73. Irace C, Mancuso G, Fiaschi E et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 17: 113-118, 2004.
74. Cauza E, Cauza Y, Hanusch-Enserer U et al. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114: 1004-1007, 2002.
75. Vis M, Nurmohamed MT, Wolbink G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32: 252-255, 2005.
76. Popa C, Netea MG, Radstake T et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64: 303-305, 2005.
77. Popa C, Barrea P, Netea MG, Stalenhoef AF, van der Meer JW Anti-TNF therapy and plasma HDL cholesterol concentration Atherosclerosis on line-jul. 2005.
78. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32: 1213-1218, 2005.
79. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 116: 305-311, 2004.
80. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 26: 2562-2571, 1999.
81. McEntegart A, Capell HA, Cretan D, Rumley A, Woodward M, Lowe GDO. Cardiovascular risk factor, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40: 640-644, 2001.
82. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheamatol 29: 875-882, 2002.
83. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 120: 26-34, 1994.
84. Del Rincon ID, Willians Y, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular evevts in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:. 2737-45, 2001.
85. Svenson KL, Lundqvist G, Wide L, Halgreen R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36: 940-3, 1987.
86. Paolisso G, Valentini G, Giugliano D, Marrazzo G, Tirri R, Gallo M et al. Evidence for peripheral impaired glucose handling in patients with connective tissue disease. Metabolism. 40: 902-7, 1991.
87. Kremers H, Nicola P, Crowson C et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50: 3450-345, 2004.
88. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93: 198-200, 2004.
89. Dessein PH, Joffe BI, Veller MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32: 435-442, 2005.
90. Stary HC, Chandler AB, Glacov S et al. A defition of initial, fatty streak, and intermediate lesions of atherosclerosis: areport from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation 89: 2462-2478, 1994.
91. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-26, 1999.
92. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
93. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511, 2003.
94. Urielli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7: 64-69, 2000.
95. Liuzzo G, Kopecky SL, Frye RL et al. Perturbation of the T cell repertoire in patients with anstable angina. Circulation 100: 2135-9, 1999.
96. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 41: 2108-16, 1998.
97. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 326: 310-318, 1992.
98. Libby P. Molecular basis of acute coronary syndromes. Circulation 91: 2844-2850, 1995.
99. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasm precede a first acute myocardial infarction in both men and women: evidence for the fibrinolitic system as an independent primary risk factor. Circulation 98: 2241-2247, 1998.
100. Ma J, Nennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 33: 1347-1352, 1999.
101. Wong M, Toh L, Wilson A et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 48: 81-99, 2003.
102. Vaudo G, Marchesi S, Gerli R et al. Endothelial disfunction in young patients with rheumatoid arthrtis and and low disease activity. Ann Rheum Dis 63: 31-36, 2005.
103. Matthews MB, Julian DG. Angina Pectoris: definition and description. In: Julian Dg, 2ed. Churchill -Living-Stone, New York p 1-2, 1985.
104. Wislowska M, Sypula S, Kowalik I. Echocardiographic findings, 24-hour electrocardiographic holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 17; 369-377, 1998.
105. Banks M, Pace A, Yitas G. Acute coronary syndromes present atipically and recurr more frequently in rheumatoid arthritis than matched controls. Arthritis Rheum 44: S53, 2001.
106. Maradit-Kremers H, Crownson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52: 402-411, 2005.
107. Warrington KJ, Kent PD, Nakajima T et al. Rheumatoid arthritis is an independent risk factor for accelerated coronary artery disease. Arthritis Rheum 44: S58, 2002.
108. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 338: 1516-1520, 1998.
109. Maclean CH, Louie K, Leake B et al. Quality of care for patients with rheumatoid arthritis. JAMA 284: 984-982, 2000.